INFUVITE PEDIATRIC (multiple vitamins injection) by Novartis. Approved for vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition (). First approved in 2001.
Drug data last refreshed 34m ago · AI intelligence enriched 6d ago
INFUVITE PEDIATRIC is a multiple vitamin injection administered intravenously to treat vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The product provides essential vitamins via IV route in hospital and clinical settings where oral supplementation is not feasible. It has been on the market since 2001 and represents a foundational therapy for nutritionally-dependent pediatric populations.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracting brand team focused on defending market share rather than growth initiatives.
Vitamin C
Only one linked job opening exists for this product, concentrated in R&D, indicating a very lean team structure typical of mature, niche therapies. Career growth on INFUVITE PEDIATRIC is likely limited; opportunities focus on defending intellectual property and optimizing formulations rather than commercialization or expansion.
Worked on INFUVITE PEDIATRIC at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
1 open roles linked to this drug